Ceftaroline Fosamil: 4 agencies, 2013–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 12.8 years separate the first record, 14 Jan 2013 at SMC (Scotland), from the most recent, 19 Nov 2025 at CIPM (Spain).
CIPM (Spain) changed its position: not recommended on 8 Jul 2021, recommended by 19 Nov 2025, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ceftaroline fosamil, 1 submission was never made — an outcome set by the company rather than the assessor.
Against its own class, ceftaroline fosamil is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class J01D average 84%.
4 distinct indication wordings are recorded for ceftaroline fosamil by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess ceftaroline fosamil, on 14 Jan 2013; CIPM (Spain) did not open a file until 8 Jul 2021 — an unusually long tail of 8.5 years between the earliest and latest system to look at it.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed ceftaroline fosamil to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales) and SMC (Scotland).
3 of the 4 agencies here assessed ceftaroline fosamil more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed ceftaroline fosamil.
The full ledger for ceftaroline fosamil reads 3 not recommended, 2 recommended, 2 restricted and 1 non-submission.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 28 Oct 2021 | Indicaciones terapéuticas autorizadas: Zinforo está indicado para el tratamiento de las siguientes infecciones en neonat… | not financed by the SNS (financed 2025-11) | source |
| CIPM (Spain) | 8 Jul 2021 | Indicaciones terapéuticas autorizadas: Zinforo está indicado para el tratamiento de las siguientes infecciones en neonat… | not financed by the SNS (financed 2025-11) | source |
| SMC (Scotland) | 15 Jan 2018 | treatment of complicated skin and soft tissue infections in children from the age of 2 months • community-acquired pneumonia in children from the age of 2 months | not recommended | source |
| PHARMAC (New Zealand) | 8 May 2014 | Multi-drug-resistant infections | PTAC advice: High · decision reached | source |
| AWMSG (Wales) | 31 Jul 2013 | Treatment of the following infections: complicated skin and soft-tissue infections (cSSTI) and community-acquired pneumo… | recommended with restrictions (full) | source |
3 further decisions for ceftaroline fosamil, across 3 agencies, are not shown here. They include the most recent record on file, 19 Nov 2025 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- cefuroxime — same ATC class J01D — Antibacterials
- meropenem — same ATC class J01D — Antibacterials
- cefiderocol — same ATC class J01D — Antibacterials
- cefazolin — same ATC class J01D — Antibacterials
- ertapenem — same ATC class J01D — Antibacterials
- elosulfase alfa — also decided by CIPM in 2025Q4
Coverage: 8 decisions for ceftaroline fosamil from 4 agencies, 2013 to 2025. Data to 7 Sep 2026. ATC class J01D — Antibacterials. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.